• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process.
【24h】

Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process.

机译：不管动脉粥样硬化过程的延长如何，内皮抗氧化剂的施用都能改善对PDE5的勃起反应。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: The lack of phosphodiesterase type 5 inhibitor effects in patients with erectile dysfunction (ED) of arterial origin may be caused by an endothelial dysfunction that causes a series of biochemical alterations leading to a reduced nitric oxide (NO) bioavailability and increased oxidative stress. AIM: The aim of this study was to evaluate the effects of the treatment with endothelial antioxidant compounds (EAC) on the erectile response to sildenafil in patients with arterial ED already treated with sildenafil (100 mg twice a week for 8 weeks). MEAN OUTCOME MEASURES: A patient was considered responsive when the 5-item International Index of Erectile Function questionnaire score increased by >5 points. METHODS: Fifty-three patients with arterial ED, hypertension, and diabetes mellitus were randomly given, for 8 weeks, EAC (1 dose/day) and, after a wash out of 8 weeks, sildenafil (100 mg) plus EAC. The patients were divided into the following four groups: A (N = 12): patients with ED alone; B (N = 14): patients with ED plus atheromasic plaques and/or increased intima-media thickness of common carotid arteries; C (N = 14): patients with ED plus lower limb artery abnormalities; and D (N = 13): patients with ED plus carotid and lower limb artery abnormalities. RESULTS: The administration of EAC plus sildenafil resulted in a significantly higher number of responsive patients (N = 36, 68%) compared with sildenafil alone (N = 24, 45%) or EAC alone (N = 17, 32%). The percentage of patients who successfully responded to the combined treatment increased in the various groups. It was 83%, 64%, 71%, and 54%, respectively, for groups A, B, C, and D. Furthermore, patients treated with EAC and sildenafil reached a successful response in a shorter length of time (3 weeks) compared with patients responsive to sildenafil (5.2 weeks) or EAC (5.7 weeks) alone. CONCLUSION: EAC administration to patients with arterial ED improved the success rate to sildenafil. These data suggest that, in such patients, a combined treatment may be considered to increase bioavailable NO and to neutralize radical oxygen species, which in turn inactive NO.
机译：简介：患有血管性勃起功能障碍（ED）的患者缺乏5型磷酸二酯酶抑制剂的作用可能是由内皮功能障碍引起的，内皮功能障碍引起一系列生化改变，导致一氧化氮（NO）生物利用度降低和氧化应激增加。目的：本研究的目的是评估在已接受西地那非（每周两次，共8周）的ED患者中，内皮抗氧化剂化合物（EAC）治疗对西地那非勃起反应对西地那非的影响。平均观察指标：当5项国际勃起功能指数问卷评分增加5分以上时，该患者被认为有反应。方法：对53例患有动脉ED，高血压和糖尿病的患者随机给予EAC 8周，每天1剂，每天冲洗8周后，加用西地那非（100 mg）加EAC。将患者分为以下四组：A（N = 12）：仅患有ED的患者; B（N = 14）：ED加动脉粥样硬化斑块和/或颈总动脉内膜中层厚度增加的患者; C（N = 14）：ED加下肢动脉异常的患者; D（N = 13）：ED加颈动脉和下肢动脉异常的患者。结果：与单独使用sildenafil（N = 24，45％）或单独使用EAC（N = 17，32％）相比，EAC加西地那非的给药导致反应的患者数量明显增加（N = 36，68％）。在各个组中，成功地对联合治疗产生反应的患者百分比有所增加。 A，B，C和D组分别为83％，64％，71％和54％。此外，接受EAC和西地那非治疗的患者在较短的时间内（3周）达到了成功的反应。与仅对西地那非（5.2周）或EAC（5.7周）有反应的患者进行比较。结论：对动脉ED患者进行EAC可提高西地那非的成功率。这些数据表明，在此类患者中，可以考虑联合治疗以增加生物利用度NO并中和自由基氧，从而使NO失活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号